Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Scientists Design World's Most Sophisticated COVID-19 Sequencing System

By LabMedica International staff writers
Posted on 30 Jul 2021
New bioinformatics software and cloud computing approaches have enabled the development of the most sophisticated COVID-19 sequencing system in the world.

The system, called CLIMB-COVID was designed for the COVID-19 Genomics UK (COG-UK) consortium, set up in March 2020 to tackle the huge challenge of rapidly sequencing SARS-CoV-2 genomes. More...
The first version of CLIMB-COVID was designed and built by researchers at the University of Birmingham (Birmingham, UK) and Cardiff University (Wales, UK) in under a month and has been instrumental in processing the sequencing data of more than 675,000 coronavirus genomes, including identifying and tracking the Alpha and Delta variants that became dominant in the UK. CLIMB-COVID also integrates new software from collaborators at the University of Edinburgh and the Centre for Genomic Pathogen Surveillance.

CLIMB-COVID enables a distributed sequencing system, harnessing sequencing capability from universities, academic institutes and the UK’s four public health agencies. The CLIMB-COVID software and database infrastructure was able to receive all this data, process it and help analyse it into interpretable outputs for public health analysts. All the data from the project has been integrated and shared in real-time. Not only has this enabled the UK’s public health agencies to work together more easily, but enabling seamless access and collaboration with academics, also enabled the early detection and evaluation of new variants of the virus. Understanding viral evolution is important for understanding how the virus is spreading in local, national and international settings. It provides valuable epidemiological information revealing the chains of transmission that must be stopped in order to stop outbreaks.

“Building this kind of decentralized sequencing system has not been possible before now, because the software infrastructure has not been available. By designing that system, we have shown how genetic sequencing can be used as a vital tool in any public health response,” said Dr. Samuel Nicholls, lead author on the paper. “The CLIMB-COVID system is open source. That means anyone in the world can access our computer code and all genomic data, and can see how we work. We have never seen such a coordinated, sustained effort to generate real-time genomic surveillance data at this scale and pace and this is why the UK is world-leading in the genomic sequencing of SARS-CoV-2.”

Related Links:
University of Birmingham
Cardiff University

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.